



## Signaling of Protein Kinases in Development and Disease

Guest Editor:

**Dr. John Zheng Fu**

Department of Pharmacology,  
University of Virginia,  
Charlottesville, VA, USA

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editor

Dear Colleagues,

Protein kinases comprise one of the largest and most abundant gene families in humans and play a pivotal role in signal transduction during tissue development, patterning, and homeostasis through the phosphorylation and functional modulation of protein substrates. Both germ-line and somatic mutations in kinase genes have been associated with many human diseases. Protein kinases are the second most targeted group for drug development. Novel therapeutic strategies to target protein kinases and intervene in cell signaling are still limited due to our incomplete understanding of their signaling mechanisms.

This Special Issue welcomes both comprehensive reviews and original articles to highlight the recent progress in the discovery of new mechanisms by which protein kinases function and human mutations disrupt kinase signaling and impact signal transduction.

Dr. John Zheng Fu

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)